Thrombin and Its Precursor in Human Cerebrospinal Fluid

Summary

The blood coagulation cascade proteolytic enzyme, thrombin, affects many cell types, including neurons and astrocytes, in which it prevents process outgrowth and induces significant morphological degeneration and even cell death. Since thrombin may contribute significantly to pathological conditions in the central nervous system (CNS), where it is synthesized locally, we measured the levels of thrombin and its precursor, prothrombin, in the cerebrospinal fluid (CSF) of 67 individuals from 6 groups: non-neurologic controls (NNC); spinal degenerative disease (SDD); peripheral nerve disease (PND); cerebrovascular, neuroimmune and seizure disorders and tumor (CNSD); traumatic brain injury (TBI) and neurodegenerative disorders (NDD). We employed a sensitive chromogenic assay utilizing the thrombin specific tripeptide substrate, S-2238, to evaluate CSF levels of thrombin and prothrombin. The latter estimated after its conversion to active enzyme by the snake venom prothrombinase, ecarin. No measurable active thrombin was detected in these CSF samples. However, activatable prothrombin was measured in all groups. The mean activatable prothrombin concentrations (in nM) were 7.26 ± 3.39 (NNC); 8.85 ± 3.09 (SDD); 6.78 ± 2.58 (PND); 6.33 ± 3.87 (CNSD); 5.10 ± 1.86 (TBI), and 7.80 ± 3.27 (NDD). Duncan’s multiple comparison test showed significant reduction (p <0.05) in prothrombin levels of the TBI group. Our data suggests that the prothrombin zymogen gains access to the CSF, likely-across either an intact or compromised blood-brain barrier (BBB), in increased amounts with age. Reduced levels in TBI patients may have diagnostic and/or prognostic value.

• References

• 1 Fenton JW. Regulation of thrombin generation and functions. Semin Thromb Heamost 1988; 14: 234-240
• 2 Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-1068
• 3 Pouyssegur J, L’Allemain G, Lenormand P, Pages G, Pavirani A, Rasmussen U, Van Obberghen-Schilling E, Vouret-Craviari V. Alpha-thrombin receptor and MAP kinases in the control of cell growth. Nouv Rev Française Hematol 1993; 35: 263-264
• 4 Grabham P, Cunningham DD. Thrombin receptor activation stimulates astrocyte proliferation and reversal of stellation by distinct pathways: Involvement of tyrosine phosphorylation. J Neurochem 1995; 64: 583-591
• 5 Gurwitz D, Cunningham DD. Thrombin modulates and reverses neuroblastoma neurite outgrowth. Proc Natl Acad Sci USA 1988; 85: 3440-3444
• 6 Suidan HS, Stone SR, Hemmings BA, Monard D. Thrombin causes neurite retraction in neuronal cells through activation of cell surface receptors. Neuron 1992; 8: 363-375
• 7 Cavanaugh KP, Gurwitz D, Cunningham DD, Bradshaw RA. Reciprocal modulation of astrocyte stellation by thrombin and protease nexin-1. J Neurochem 1990; 54: 1735-1743
• 8 Beecher KL, Andersen TT, Fenton JW, Festoff BW. Thrombin receptor peptides induce shape change in neonatal murine astrocytes in culture. J Neurosci Res 1994; 37: 108-115
• 9 Fenton JW. Thrombin. Ann NY Acad Sci 1986; 485: 05-15
• 10 Vaughan PJ, Pike CJ, Cotman CW, Cunningham DD. Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults. J Neurosci 1995; 15: 5389-5401
• 11 Smith-Swintosky VL, Zimmer S, Fenton JW II, Mattson MP. Protease nexin-1 and thrombin modulate neuronal Ca2+ homeostasis and sensitivity to glucose deprivation-induced injury. J Neurosci 1995; 15: 5840-5850
• 12 Akiyama H, Ikeda K, Kondo H, McGeer PL. Thrombin accumulation in brains of patients with Alzheimer’s disease. Neurosci Lett 1992; 146: 152-154
• 13 Nishino A, Suzuki M, Ohtani H, Motohashi O, Umezawa K, Nagura H, Yoshimoto T. Thrombin may contribute to the pathophysiology of central nervous system injury. J Neurotrauma 1993; 10: 167-179
• 14 Dihanich M, Kaser M, Reinhard E, Cunningham D, Monard D. Prothrombin mRNA is expressed by cells of the nervous system. Neuron 1991; 6: 575-581
• 15 Deschepper CF, Bigomia V, Berens ME, Lapointe MC. Production of thrombin and antithrombin III by brain and astroglial cell cultures. Brain Res Mol Brain Res 1991; 11: 355-358
• 16 Monard D. Tinkering with certain blood components can engender distinct functions in the nervous system. Perspect Dev Neurobiol 1993; 1: 165-168
• 17 Ho GJ, Smirnova IV, Akaaboune M, Hantai D, Festoff BW. Serine proteases and their serpin inhibitors in Alzheimer’s disease. Biomed Pharmacother 1994; 48: 296-304
• 18 Smirnova IV, Ho GJ, Fenton JWI, Festoff BW. Extravascular proteolysis and the nervous system: serine protease/serpin balance. Semin Thromb Hemost 1994; 20: 426-432
• 19 Festoff BW, Smirnova IV, Ma JX, Citron BA. Thrombin, its receptor and protease nexin I its potent serpin in the nervous system. Semin Thromb Hemost 1996; 22: 267-271
• 20 Dube RK, Sahaa PK, Dube B, Katiyar BC, Rao PV. Fibrinogen, fibrinogen degradation products and fibrinolytic activity in cerebrospinal fluid in stroke. Ind J Med Res 1980; 72: 454-457
• 21 Schisano G, Franco A, Nina P, Papa ML, Iannuzzi M, De Biase R, Caldora M. Monitoring of fibrin and fibrinogen degradation products (FDP) in the cerebrospinal fluid of patients with subarachnoid haemorrhage due to ruptured aneurysm. Report of 55 cases. J Neurosurg Sci 1994; 38: 77-86
• 22 Suzuki M, Ogawa A, Sakurai Y, Nishino A, Venohara K, Mizoi K, Yoshimoto T. Thrombin activity in cerebrospinal fluid after subarachnoid hemorrhage. Stroke 1992; 23: 1181-1182
• 23 Lottenberg R, Christensen U, Jackson CM, Coleman PL. Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. Methods Enzymol 1981; 80: 341-361
• 24 Duncan DB. Multiple range and multiple F-test. Biometrics 1955; 11: 01-42
• 25 Fenton JW, Villanueva GB, Ofosu FA, Maraganore JM. Thrombin inhibition by hirudin: how hirudin inhibits thrombin. Haemostasis 1991; (Suppl. 21) 1: 27-31
• 26 Garton MJ, Keir G, Lakshmi MV, Thompson EJ. Age-related changes in cerebrospinal fluid protein concentrations. J Neurol Sci 1991; 104: 74-80
• 27 Harrington MG, Merril CR, Torrey EF. Differences in cerebrospinal fluid proteins between patients with schizophrenia and normal persons. Clin Chem 1985; 31: 722-726
• 28 Matsubara E, Hirai S, Amari M, Shoji M, Yamaguchi H, Okamoto K, Ishiguro K, Harigaya Y, Wakabayashi K. Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Ann Neurol 1990; 28: 561-567
• 29 Colover J. Immunoassay of P2 protein in cerebrospinal fluid in neurological disorders. J Clin Pathol 1991; 44: 69-72
• 30 Gijbels K, Proost P, Masure S, Carton H, Billiau A, Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res 1993; 36: 432-440
• 31 Schwagerl AL, Mohan PS, Cataldo AM, Vonsattel JP, Kowall NW, Nixon RA. Elevated levels of the endosomal-lysosomal proteinase cathepsin D in cerebrospinal fluid in Alzheimer disease. J Neurochem 1995; 64: 443-446
• 32 Rozniecki JJ, Hauser SL, Stein M, Lincoln R, Theoharides TC. Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 1995; 37: 63-66
• 33 Akenami FO, Siren V, Koskiniemi M, Siimes MA, Teravainen H, Vaheri A. Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases. J Clin Pathol 1996; 49: 577-580
• 34 Schwartz BS, Levy GA, Fair DS, Edgington TS. Murine lymphoid procoagulant activity induced by bacterial lipopolysaccharide and immune complexes is a monocyte prothrombinase. J Exp Med 1982; 155: 1464-1479
• 35 Lindahl U, Pejler G, Bogwald J, Seljelid R. A prothrombinase complex of mouse peritoneal macrophages. Arch Biochem Biophys 1989; 273: 180-188
• 36 Sekiya F, Usui H, Inoue K, Fukudome K, Morita T. Activation of prothrombin by a novel membrane-associated protease. An alternative pathway for thrombin generation independent of the coagulation cascade. J Biol Chem 1994; 269: 32441-32445
• 37 Tumell AS, Brant DP, Brown GR, Finney M, Gallimore PH, Kirk CJ, Pagliuca TRV, Campbell CJ, Michell RH, Grand RJA. Regulation of neurite outgrowth from differentiated human neuroepithelial cells: A comparison of the activities of prothrombin and thrombin. Biochem J 1995; 308: 965-973
• 38 Benzakour O, Kanthou C, Lupu F, Dennehy U, Goodwin C, Scully MF, Kakkar VV, Cooper DN. Prothrombin cleavage by human vascular smooth muscle cells: A potential alternative pathway to the coagulation cascade. J Cell Biochem 1995; 59: 514-528
• 39 Festoff BW, Rao JS, Chen M. Protease nexin I thrombin- and urokinase- inhibiting serpin concentrated in normal human cerebrospinal fluid. Neurology 1992; 42: 1361-1366
• 40 Suzuki M, Motohashi O, Nishino A, Shiina V, Mizoi K, Yoshimoto T, Kameyama M, Onuma T. Diphasic increase in thrombin-antithrombin III complex in blood from the internal jugular vein following severe head injury. Thromb Haemost 1994; 71: 155-157
• 41 Baker JB, Knauer DJ, Cunningham DD. Protease nexins: secreted protease inhibitors that regulate protease actions at and near the cell surface. In: Conn PM. ed The receptors. New York: Academic Press; 1986. pp 153-172
• 42 Stone SR, Nick H, Hofsteenge J, Monard D. Glial-derived neurite-promoting factor is a slow-binding inhibitor of trypsin thrombin, and urokinase. Arch Biochem Biophys 1987; 252: 237-244
• 43 Smirnova IV, Ma JXY, Citron BA, Ratzlaff KT, Gregory EJ, Akaaboune M, Festoff BW. Neural thrombin and protease nexin kinetics after murine peripheral nerve injury. J Neurochem 1996; 67: 2188-2199
• 44 Forsyth KD, Talbot V, Beckman I. Endothelial serpins – protectors of the vasculature?. Clin Exp Immunol 1994; 95: 277-282
• 45 Rayford A, Rao JS, Festoff BW. Characterization of the serpin lpha 1- antichymotrypsin, in normal human cerebrospinal fluid. J Neurochem 1992; 58: 88-94
• 46 Abraham CR. The role of the acute-phase protein alpha 1-antichymotrypsin in brain dysfunction and injury. Res Immunol 1992; 143: 631-636
• 47 Cunningham DD, Pulliam L, Vaughan PJ. Protease nexin-1 and thrombin: Injury-related processes in the brain. Thromb Haemost 1993; 70: 168-171
• 48 Nishino A, Suzuki M, Yoshimoto T, Otani H, Nagura H. A novel aspect of thrombin in the tissue reaction following central nervous system injury. Acta Neurochir Suppl Wien 1994; 60: 86-88
• 49 Lee KR, Betz AL, Keep RF, Chenevert TL, Kim S, Hoff JT. Intracerebral infusion of thrombin as a cause of brain edema. J Neurosurg 1995; 83: 1045-1050
• 50 Lee KR, Colon GP, Betz AL, Keep RF, Kim S, Hoff JT. Edema from intracerebral hemorrhage: The role of thrombin. J Neurosurg 1996; 84: 91-96
• 51 Wagner SL, Geddes JW, Cotman CW, Lau AL, Gurwitz D, Isackson PJ, Cunningham DD. Protease nexin-1, an antithrombin with neurite outgrowth activity is reduced in Alzheimer disease. Proc Natl Acad Sci USA 1989; 86: 8284-8288
• 52 Vaughan PJ, Su J, Cotman CW, Cunningham DD. Protease nexin-1, a potent thrombin inhibitor is reduced around cerebral blood vessels in Alzheimer’s disease. Brain Res 1994; 668: 160-170
• 53 Grabham PW, Monard D, Gallimore PH, Grand RJA. Modulation of human neurite outgrowth by serine proteases – a comparison of the interaction of thrombin and prothrombin with glia-derived nexin. Eur J Neurosci 1991; 3: 663-668